Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
23.12
+1.56 (+7.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
May 09, 2023
Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate.
Via
InvestorPlace
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
May 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
May 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
April 26, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
3 Big Reasons to Sell Cassava Sciences Stock Right Now
February 01, 2023
It isn't about running out of money, but it's still laden with risk.
Via
The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today
January 31, 2023
Via
Benzinga
Short Interest Sector Focus: Healthcare Sector
April 04, 2023
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector...
Via
Benzinga
Why Is Asana (ASAN) Stock Up 24% Today?
March 09, 2023
Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report.
Via
InvestorPlace
ETSY Stock Falls on Double Downgrade
March 09, 2023
Etsy (ETSY) stock is falling on Thursday after the e-commerce company's shares were hit with a double downgrade from Jefferies.
Via
InvestorPlace
3 Short-Squeeze Stocks to Keep on Your Radar
March 09, 2023
These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run.
Via
InvestorPlace
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
March 09, 2023
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.
Via
InvestorPlace
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
January 24, 2023
Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall.
Via
InvestorPlace
$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today
January 18, 2023
Via
Benzinga
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
March 09, 2023
Gainers
Via
Benzinga
Tesla, Apple, Cassava Sciences, MongoDB, Asana: Why These Five Stocks Are Drawing Investors' Attention Today?
March 08, 2023
Via
Benzinga
Why Cassava Sciences Stock Is Surging After Hours
March 08, 2023
Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 08, 2023
Via
Benzinga
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
February 28, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
February 24, 2023
These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch.
Via
InvestorPlace
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
February 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
January 24, 2023
Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes.
Via
Benzinga
Cassava Sciences Stock Is Diving: What's Going On?
January 24, 2023
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading significantly lower Tuesday after the company announced top-line clinical results from a Phase 2 study
Via
Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 24, 2023
Via
Benzinga
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
January 24, 2023
Via
Benzinga
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
January 24, 2023
Some patients improved while taking the company's twice-daily pill.
Via
Investor's Business Daily
3M, Magna International And Other Big Stocks Moving Lower On Tuesday
January 24, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
January 24, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell...
Via
Benzinga
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
January 24, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.